Marksans Pharma announced a resilient performance for Q3FY26, marked by a 10.6% YoY increase in operating revenue. EBITDA margin also expanded by 217 bps YoY. The company highlighted robust traction in the US and UK markets, driven by new product launches and market share gains. The company continues to strategically invest in global expansion.
Financial Performance Highlights
Marksans Pharma delivered strong financial results for Q3FY26:
- Operating revenue reached Rs. 754.4 cr, a 10.6% increase compared to the same quarter last year.
- Gross profit rose to Rs. 438.2 cr, up by 14.3% YoY, with a gross margin of 58.1%.
- EBITDA stood at Rs. 160.7 cr, with EBITDA margin expanding to 21.3%.
- Earnings per share (EPS) were reported at Rs. 2.5.
Nine-Month Performance (9MFY26)
The company also reported its financial performance for the nine-month period ended December 31, 2025:
- Operating revenue: Rs. 2,094.8 cr, up by 9.4% YoY.
- Gross profit: Rs. 1,208.2 cr, an increase of 10.3% YoY, resulting in a gross margin of 57.7%.
- EBITDA reached Rs. 405.4 cr, with an EBITDA margin of 19.4%.
- EPS: Rs. 6.0.
Segmental Performance
A breakdown of revenue by geographical segment shows:
- US & North America: Revenues of Rs. 412.4 cr for Q3FY26, a 16.9% increase YoY, driven by strong volumes.
- UK & Europe: Revenues of Rs. 258.2 cr for Q3FY26, showing marginal growth of 0.2%, attributed to new launches and favorable currency movements.
- Australia & New Zealand: Revenue of Rs. 61.4 cr. in Q3FY26, up 30.1%.
- Rest of World: Rs. 22.4 cr in Q3FY26.
Other Key Highlights
- Cash generated from operations in 9MFY26: ₹ 263.2 cr.
- Capex incurred during 9MFY26: ₹ 97.0 cr.
- Cash balance as of December 31, 2025: ₹ 824.2 cr.
- Research and development (R&D) expenses in 9MFY26: ₹ 62.0 cr, representing 3.0% of consolidated revenue.
Source: BSE
